<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728843</url>
  </required_header>
  <id_info>
    <org_study_id>LA48-0215</org_study_id>
    <nct_id>NCT02728843</nct_id>
  </id_info>
  <brief_title>Study of Parkinson's Early Stage With Deferiprone</brief_title>
  <acronym>SKY</acronym>
  <official_title>A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in
      patients with Parkinson's disease. Participants will be randomized to receive one of four
      different dosages of deferiprone or placebo, and will take the assigned study product twice a
      day for nine months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 140 patients who have been diagnosed with Parkinson's disease within
      the last 3 years and are currently taking antiparkinsonian medication. There are four dosage
      cohorts, with patients in each cohort receiving either deferiprone tablets or placebo. At the
      baseline visit, participants will be randomized to a dosage cohort and to either active
      product or placebo within that cohort, and will take the assigned study product twice-daily
      for 9 months. They will come back to the study site for assessments at Months 1, 2, 3, 4, 5,
      6, and 9, and will need to have their blood count checked weekly, at either the study site or
      a local laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">September 4, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on the Part III subscale of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in motor examination, as assessed by score on Part III of the MDS-UPDRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total score on the MDS-UPDRS</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in total score on the MDS-UPDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on the Part I, Part II, and Part IV subscales of the MDS-UPDRS</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in non-motor experiences of daily living, motor experiences of daily living, and motor complications, as assessed by scores on Parts I, II, and IV, respectively of the MDS-UPDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined scores from Parts II and III of the MDS-UPDRS</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in combined scores from Parts II and III of the MDS-UPDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Montreal Cognitive Assessment (MoCA) test</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in overall cognitive function as assessed by MoCA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics measures of oxidative stress biomarkers</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics measures of inflammatory factor biomarkers</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to Month 9 in inflammatory factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until need for rescue medication</measure>
    <time_frame>Up to nine months</time_frame>
    <description>Time elapsed until the patient is deemed to require a change or increase in antiparkinsonian medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of deferiprone</measure>
    <time_frame>Nine months</time_frame>
    <description>Number of subjects with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for serum deferiprone and deferiprone 3-O-glucuronide</measure>
    <time_frame>4 hours</time_frame>
    <description>Maximum measured serum concentration. Blood samples collected at baseline and Month 3, pre-dose and at 2 hours and 4 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for serum deferiprone and deferiprone 3-O-glucuronide</measure>
    <time_frame>4 hours</time_frame>
    <description>Time to maximum observed serum concentration. Blood samples collected at baseline and Month 3, pre-dose and at 2 hours and 4 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>4 hours</time_frame>
    <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples collected at baseline and Month 3, pre-dose and at 2 hours and 4 hours post-dose.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Deferiprone 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferiprone 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferiprone 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferiprone 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>600 mg tablets</description>
    <arm_group_label>Deferiprone 1200 mg</arm_group_label>
    <arm_group_label>Deferiprone 300 mg</arm_group_label>
    <arm_group_label>Deferiprone 600 mg</arm_group_label>
    <arm_group_label>Deferiprone 900 mg</arm_group_label>
    <other_name>DFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets that match the deferiprone tablets in appearance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥18 to &lt; 80 years

          -  Body weight ≥60 kg but ≤100 kg

          -  Parkinson's disease diagnosed

          -  Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (≥1.0 x 10^9/L for Black population) at
             screening

          -  On a stable dose for at least 3 months prior to the screening visit of any of the
             following treatments at an L-dopa equivalent daily dose of up to 600 mg:

          -  Dopaminergic agonist alone

          -  L-dopa alone

          -  Combination therapy with dopaminergic agonist and L-dopa

          -  Rasagiline

          -  At an early stage of the disease, without motor fluctuations and/or L-dopa-induced
             dyskinesia

        Exclusion Criteria:

          -  Diagnosis of Parkinson's disease more than 3 years prior to screening visit

          -  Hoehn and Yahr stage ≥ 3

          -  Atypical or secondary Parkinsonism without dopa-sensitivity (e.g., vascular
             parkinsonism, supranuclear palsy, multisystem atrophy)

          -  Progressing Axis I psychiatric disorders (psychosis, hallucinations, compulsive
             disorders, substance addiction, bipolar disorder, severe depression, anxiety) as
             assessed in a semi-structured interview in accordance with the Diagnostic and
             Statistical Manual of Mental Disorders

          -  Not stabilized in terms of the current antiparkinsonian therapeutic regimen: already
             requires dose adaptation and/or is likely to require any change in dopamine therapy
             over the duration of the trial

          -  Current treatment with bromocriptine

          -  Current treatment with any antiparkinsonian drug other than those listed in the
             inclusion criteria

          -  Current treatment with coenzyme Q10 or idebenone. (Patients who are on these
             medications but stop taking them at least 2 weeks prior to baseline may be enrolled.)

          -  Current use of a Deep Brain Stimulation (DBS) system. (Patients who previously had a
             DBS system but have had it removed may be enrolled.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Fradette, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ApoPharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux, Centre Expert Parkinson</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille, Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicoll - Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan, Hôpital Pierre Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinriche-Heine Universität Düsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Kiel, Neurologie</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Clinical Ageing Research Unit</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Deferiprone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

